Nexium Control formulation

Image of Nexium Control breaking the cycle of heartburn

Antacids and alginates provide short term relief

Antacids react with gastric acid, neutralising it.

Alginates form a temporary physical barrier (or raft) on top of the stomach helping to prevent the contents from escaping through the sphincter. Their effectiveness depends on the stomach contents, with them being less effective if taken during a meal or when lying down.

For both antacids and alginates, once the stomach empties, their effects cease. Repeated dosing is necessary to provide relief from newly secreted acid.

This need for repeat dosing can lead to patients developing a ‘burn-suffer-treat' reactive cycle which may not provide the sustained relief from frequent heartburn that they need.

Image of Nexium Control breaking the cycle of heartburn

Nexium Control provides long-lasting relief

Nexium Control, with esomeprazole, reduces the production of stomach acid for 24-hour protection, treating the cause and symptoms of heartburn. Allowing time for the oesophagus to recover from the acid irritation.

Protection is achieved with the convenience of once a day dosing*.

*Some people experience relief within a day, though for some, it may take 2 – 3 days for complete relief.

Find out more

No other OTC PPI lasts longer1,2

Esomeprazole passes through the liver to the bloodstream more efficiently (with less excretion) compared to omeprazole.2

Nexium Control tablets pack

Nexium Control 20mg Gastro-Resistant Tablets (Esomeprazole)

Up to 24 hour relief and protection from frequent heartburn with just one pill a day.

Gastro-resistant tablets.

Available in pack sizes of 7 and 14 tablets.

Nexium Control Capsules pack

Nexium Control 20mg Gastro-Resistant Capsules (Esomeprazole)

Up to 24 hour relief and protection from frequent heartburn with just one pill a day.

Easy to swallow mini capsules: 53% smaller than tablets.*

Available in pack size of 14

*based on volume of tablets vs. capsules

Product Information

Nexium Control 20 mg gastro resistant tablets and hard capsules. Esomeprazole. Indications: The short term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg esomeprazole (one tablet or capsule) per day. It might be necessary to take the tablets or capsules for 2-3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Warnings and precautions: Patients should be instructed to consult a doctor if: They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis. They have had previous gastric ulcer or gastrointestinal surgery. They have been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks. They have jaundice or severe liver disease. They are aged over 55 years with new or recently changed symptoms. Patients with long term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Patients over 55 years taking any non prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor. Patients should not take Nexium Control as a long term preventive medicinal product. Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile. Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test. Co-administration of esomeprazole with atazanavir is not recommended. If the combination of atazanavir with a PPI is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir. Esomeprazole 20 mg should not be exceeded. Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with medicinal products metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole although the clinical relevance of this interaction is uncertain. The use of esomeprazole with clopidogrel should be discouraged. Patients should not take another PPI or H2 antagonist concomitantly. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of PPI treatment. Proton pump inhibitors are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Nexium Control. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors. This medicinal product contains sugar spheres (sucrose). Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase isomaltase insufficiency should not take this medicinal product. Side effects: See SPC for full details. Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash urticaria. Rare: leukopenia, thrombocytopenia, hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock, hyponatraemia, agitation, confusion, depression, taste disturbance, blurred vision, bronchospasm, stomatitis, gastrointestinal candidiasis, hepatitis with or without jaundice, alopecia, photosensitivity, arthralgia, myalgia, malaise, increased sweating. Very rare: agranulocytosis, pancytopenia, aggression, hallucinations, hepatic failure, hepatic encephalopathy in patients with pre-existing liver disease, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), muscular weakness, interstitial nephritis, gynaecomastia. Not known: hypomagnesaemia; severe hypomagnesaemia can correlate with hypocalcaemia; hypomagnesaemia may also result in hypokalaemia, microscopic colitis, subacute cutaneous lupus erythematosus SCLE. Legal category: GSL. Product licence number: PLGB 44673/0221 and PLGB 44673/0222. MAH: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, Brentford, TW8 9GS RRP: Pack of 7 tablets RRP £6.99, pack of 14 tablets RRP £11.99. Pack of 14 capsules RRP £12.99. The prices include VAT. Text prepared: January 2021

Nexium – 24 hour heartburn relief with just one pill

Book icon

Educational Resources

Access educational resources to support your team’s understanding of heartburn and its management.

FIND OUT MORE

Stomach icon

Heartburn

Find out more about causes of heartburn and management options.

FIND OUT MORE

Sign up icon

Sign up for updates

For news, updates and more, click the link below to sign up and be on our mailing list.

Register now